44 completed, 4 recruiting, 2 active not recruiting, 2 withdrawn. 26 Phase 3, 8 Phase 2, 8 Phase 4, 7 Phase 1, 3 Not applicable.
Follow vilanterol: new trials by email Literature Review of vilanterol trials Research Report on vilanterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VENTURI (VENTilation Using Respiratory Imaging) Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder - Asthma | Phase 2 | Recruiting | University of Alabama at Birmingham | 20 | 2026-03-15 | 2026-04-13 |
| Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD Tiotropium, Olodaterol, Umeclidinium - COPD (Chronic Obstructive Pulmonary Disease) | Not applicable | Suspended | Medical University of Bialystok | 100 | 2024-03-11 | 2026-10-02 |
| Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ) - COPD (Chronic Obstructive Pulmonary Disease) | Phase 4 | Recruiting | University of Tennessee Graduate School of Medicine | 72 | 2023-12-05 | 2026-10-19 |
| Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure Vilanterol / Umeclidinium (25/62.5 mcg), Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg - COPD Bronchitis, Pollution Related Respiratory Disorder | Phase 4 | Unknown | National Institute of Respiratory Diseases, Mexico | 128 | 2023-11-15 | 2024-08-26 |
| U-LABA/ICS Effects on Exercise Performance, Vilanterol Vilanterol and Fluticasone Furoate (low dose), Vilanterol and Fluticasone Furoate (high dose), Placebo - Exercise Performance | Not applicable | Recruiting | Morten Hostrup, PhD | 30 | 2023-10-03 | 2025-04-10 |
| Role of Lung Function for Exercise Capacity in Well-trained Individuals Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo - Exercise Performance | Not applicable | Recruiting | Morten Hostrup, PhD | 60 | 2023-10-03 | 2025-04-09 |
| A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD) Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 9117 | 2021-12-17 | 2023-10-19 | |
| Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure Umeclidinium/vilanterol, Placebo - Copd, Heart Failure | Phase 4 | Completed | Luis Puente Maestu | 60 | 2021-05-21 | 2026-09-21 |
| Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery Vilanterol and Umeclidinium Bromide, Placebo - Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | Samsung Medical Center | 204 | 2021-04-01 | 2026-06-26 |
| A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD) Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 11296 | 2019-06-10 | 2021-11-15 | |
| A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. AZD8871, Anoro® Ellipta® - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | AstraZeneca | 73 | 2018-10-10 | 2020-12-17 |
| The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma Fluticasone Furoate/Vilanterol, Fluticasone Furoate, Salbutamol/Albuterol - Asthma | Phase 4 | Withdrawn | GlaxoSmithKline | 2018-03-07 | 2018-01-29 | |
| Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics Anoro Ellipta, Arnuity Ellipta - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | University of Virginia | 95 | 2017-11-05 | 2024-11-18 |
| Effect of Vilanterol on Methacholine Challenge Results Vilanterol and Fluticasone Furoate, Fluticasone Furoate, Placebos - Asthma | Phase 4 | Completed | University of Saskatchewan | 17 | 2017-10-13 | 2018-10-11 |
| INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol Tiotropium & olodaterol, fluticasone furoate & vilanterol - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | University of Dundee | 80 | 2017-06-01 | 2020-07-20 |
| Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol - Chronic Obstructive Pulmonary Disease COPD | Phase 3 | Completed | AstraZeneca | 1119 | 2017-05-25 | 2019-05-22 |
| A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg, Fluticasone furoate 100 mcg + Vilanterol 25 mcg, Umeclidinium 62.5 mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | GlaxoSmithKline | 2016-06-01 | 2016-07-22 | |
| Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB) Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler - Asthma | Phase 4 | Completed | GlaxoSmithKline | 75 | 2016-05-25 | 2019-07-16 |
| A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients. Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg), Placebo - Asthma | Phase 2 | Completed | GlaxoSmithKline | 28 | 2016-04-29 | 2018-08-28 |
| Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) Batefenterol, Umeclidinium/ Vilanterol, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 325 | 2015-11-06 | 2019-07-16 |
Showing 20 of 54. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (35) · Asthma (18) · Cardiovascular Diseases (2) · Emphysema (2) · Bronchitis, Chronic (1) · Carcinoma, Non-Small-Cell Lung (1) · Dyspnea (1) · Heart Failure (1) · Motor Activity (1) · Renal Insufficiency (1) · Respiratory Hypersensitivity (1)
GlaxoSmithKline (36) · AstraZeneca (2) · Boehringer Ingelheim (2) · Morten Hostrup, PhD (2) · Novartis Pharmaceuticals (2) · Luis Puente Maestu (1) · Medical University of Bialystok (1) · National Institute of Respiratory Diseases, Mexico (1) · Queen's University (1) · Samsung Medical Center (1) · University of Alabama at Birmingham (1) · University of Dundee (1) · University of Saskatchewan (1) · University of Tennessee Graduate School of Medicine (1) · University of Virginia (1)
United States (26) · Germany (21) · Poland (11) · Russia (11) · Ukraine (11) · Canada (10) · Romania (9) · Spain (9) · Argentina (8) · South Korea (8) · United Kingdom (8) · Czechia (7) · South Africa (7) · Chile (6) · Hungary (6)
Morten Hostrup, PhD (2) · Denis E O'Donnell, MD, FRCPC (1) · Don Cockcroft, MD (1) · James Chalmers, MBChB, MRCP (1) · Kun Qing, PhD (1) · Luis Puente-Maestu, Prof (1) · Robert M Mroz, professor (1) · Yun M Shim, MD (1)
PMID 24998880, PMID 28993871, PMID 36472162, PMID 37012070, PMID 20956145, PMID 23018908, PMID 23155808, PMID 23681559, PMID 24114969, PMID 24200619, PMID 24603195, PMID 24928338, PMID 25146558, PMID 25565796, PMID 25830381, PMID 26006754, PMID 26286141, PMID 26291137, PMID 26550687, PMID 26651333, PMID 27044326, PMID 27203508, PMID 27418551, PMID 27767328, PMID 27796912, PMID 28137501, PMID 28416587, PMID 28737971, PMID 28903864, PMID 28947039, PMID 28961020, PMID 29348179, PMID 29406772, PMID 29412688, PMID 29442524, PMID 29668352, PMID 29972089, PMID 30001712, PMID 30017826, PMID 30053956, PMID 30053967, PMID 30165984, PMID 30815468, PMID 31068182, PMID 31258919, PMID 31267366, PMID 31281061, PMID 31321713, PMID 31819401, PMID 31833441
2015 (1), 2016 (1), 2017 (1), 2019 (1)